Overview

AZD6738 for Patients With Progressive MDS or CMML

Status:
Recruiting

Trial end date:
2025-05-31

Target enrollment:

Participant gender:

Summary

This research study is studying a research drug called AZD6738 as a possible treatment for Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia .

Phase:

Phase 1

Details

Lead Sponsor:

Massachusetts General Hospital

Collaborator:

AstraZeneca